Hansa Biopharma Ab
Clinical trials sponsored by Hansa Biopharma Ab, explained in plain language.
-
Breakthrough drug may give kidney transplants to those previously turned away
Disease control CompletedThis study tested a drug called imlifidase in 64 people with very high antibody levels (cPRA ≥99.9%) who were waiting for a kidney transplant. The goal was to see if imlifidase could help them receive a kidney from a deceased donor and improve kidney function after one year compa…
Phase: PHASE3 • Sponsor: Hansa Biopharma AB • Aim: Disease control
Last updated Jun 16, 2026 23:21 UTC
-
Breakthrough drug may give hope to kidney patients rejected for transplant
Disease control CompletedThis study tested a drug called imlifidase in 113 highly sensitized kidney patients who had a positive crossmatch against a deceased donor. The drug was given before transplant to reduce the risk of rejection. The main goal was to see how many patients still had a working kidney …
Phase: PHASE3 • Sponsor: Hansa Biopharma AB • Aim: Disease control
Last updated Jun 16, 2026 12:53 UTC